This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

AZD2624 Multiple Ascending Dose Study in Japan (JMAD)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 11, 2008
Last updated: July 15, 2009
Last verified: July 2009
This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624

Condition Intervention Phase
Healthy Safety Drug: AZD2624 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2624 When Given in Multiple Ascending Oral Doses in Young Healthy Male Japanese Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To assess the safety and tolerability of multiple ascending oral doses of AZD2624 in young healthy male Japanese subjects compared to placebo by assessment of adverse events, vital signs, physical examinations, laboratory parameters, ECGs and EEGs [ Time Frame: All assessments are made at each visit, at least daily, during the study. ]

Secondary Outcome Measures:
  • To evaluate and characterize the pharmacokinetics of AZD2624 and its metabolites when given orally in multiple ascending doses of AZD2624 to young healthy male Japanese subjects by assessment of drug concentration in plasma [ Time Frame: Blood samples will be taken before and after study drug administration. ]
  • Identification of genes that influence the disposition, efficacy, safety and tolerability of AZD2624 [ Time Frame: A single blood sample will be obtained ]

Estimated Enrollment: 30
Study Start Date: May 2008
Study Completion Date: August 2008
Arms Assigned Interventions
Experimental: 1 Drug: AZD2624
oral suspension, 3 doses
Placebo Comparator: 2 Drug: Placebo


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy young male Japanese volunteers

Exclusion Criteria:

  • Significant illness, as judged by the investigator, within 2 weeks of screening visit or Day 1
  • Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit or Day 1
  • Blood loss in excess of 200 mL within 30 days of screening visit or Day 1, in excess of 400 mL within 90 days of screening visit or Day 1, or in excess of 1200 mL within 1 year of screening visit or Day 1
  • Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator at screening or pre first dose
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00696865

Research Site
Kanagawa, Japan
Sponsors and Collaborators
Principal Investigator: Yuji Kumagai, MD, PhD Kitasato University East Hospital, Kanagawa, Japan
  More Information

Responsible Party: Mark A. Smith, MD, PhD - Medical Science Sr. Director, AstraZeneca Pharmaceuticals Identifier: NCT00696865     History of Changes
Other Study ID Numbers: D0970C00006
Study First Received: June 11, 2008
Last Updated: July 15, 2009

Keywords provided by AstraZeneca:
Phase I processed this record on June 23, 2017